Extended preoperative chemotherapy, extent of liver resection and blood transfusion are predictive factors of liver failure following resection of colorectal liver metastasis

2013 ◽  
Vol 39 (4) ◽  
pp. 380-385 ◽  
Author(s):  
H.S.C. Ribeiro ◽  
W.L. Costa ◽  
A.L. Diniz ◽  
A.L. Godoy ◽  
P. Herman ◽  
...  
2020 ◽  
Author(s):  
Mihai-Calin Pavel ◽  
Raquel Casanova ◽  
Laia Estalella ◽  
Robert Memba ◽  
Erik Llàcer-Millán ◽  
...  

Abstract Introduction: Liver resection (LR) in patients with liver metastasis from colo-rectal cancer remains the only curative treatment. Perioperative chemotherapy improves prognosis of these patients. However, there are concerns regarding the effect of preoperative chemotherapy on liver regeneration, which is a key event in avoiding liver failure after LR. The primary objective of this systematic review is to assess the effect of neoadjuvant chemotherapy on liver regeneration after (LR) or portal vein embolization (PVE) in patients with liver metastasis from colo-rectal cancer. The secondary objectives are to evaluate the impact of the type of chemotherapy, number of cycles and time between end of treatment and procedure (LR or PVE) and to investigate whether there is an association between degree of hypertrophy and postoperative liver failure.Methods: The design of this systematic review will follow the current recommendations of PRISMA. After an exhaustive literature search with pre-established criteria, two researchers will individually screen the identified records, according to a list of inclusion and exclusion criteria. Primary outcome will be future liver remnant regeneration rate. All data will be registered in a predesigned database. In the event of a substantial heterogeneity of selected articles, a narrative systematic review will be performed.Discussion: The results of this systematic review may help to better identify the patients affected by liver metastasis that could present low regeneration rates after neoadjuvant chemotherapy. These patients are at risk to develop liver failure after extended hepatectomies and therefore are not good candidates for such aggressive procedures.Systematic Review Registration: PROSPERO registration number: CRD42020178481 (July 5th 2020).


2010 ◽  
Vol 24 (8) ◽  
pp. 2044-2047 ◽  
Author(s):  
M. A. Machado ◽  
F. F. Makdissi ◽  
R. C. Surjan ◽  
G. T. Kappaz ◽  
N. Yamaguchi

2019 ◽  
Vol 10 (12) ◽  
pp. 2619-2627 ◽  
Author(s):  
Jianhong Peng ◽  
Yixin Zhao ◽  
Qiuyun Luo ◽  
Hao Chen ◽  
Wenhua Fan ◽  
...  

2016 ◽  
Vol 88 (1-2) ◽  
pp. 66-70 ◽  
Author(s):  
Sanjay Pandanaboyana ◽  
Richard Bell ◽  
Alan White ◽  
Samir Pathak ◽  
Ernest Hidalgo ◽  
...  

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Mihai-Calin Pavel ◽  
Raquel Casanova ◽  
Laia Estalella ◽  
Robert Memba ◽  
Erik Llàcer-Millán ◽  
...  

Abstract Introduction Liver resection (LR) in patients with liver metastasis from colorectal cancer remains the only curative treatment. Perioperative chemotherapy improves prognosis of these patients. However, there are concerns regarding the effect of preoperative chemotherapy on liver regeneration, which is a key event in avoiding liver failure after LR. The primary objective of this systematic review is to assess the effect of neoadjuvant chemotherapy on liver regeneration after (LR) or portal vein embolization (PVE) in patients with liver metastasis from colorectal cancer. The secondary objectives are to evaluate the impact of the type of chemotherapy, number of cycles, and time between end of treatment and procedure (LR or PVE) and to investigate whether there is an association between degree of hypertrophy and postoperative liver failure. Methods This meta-analysis will include studies reporting liver regeneration rates in patients submitted to LR or PVE. Pubmed, Scopus, Web of Science, Embase, and Cochrane databases will be searched. Only studies comparing neoadjuvant vs no chemotherapy, or comparing chemotherapy characteristics (bevacizumab administration, number of cycles, and time from finishing chemotherapy until intervention), will be included. We will select studies from 1990 to present. Two researchers will individually screen the identified records, according to a list of inclusion and exclusion criteria. Primary outcome will be future liver remnant regeneration rate. Bias of the studies will be evaluated with the ROBINS-I tool, and quality of evidence for all outcomes will be determined with the GRADE system. The data will be registered in a predesigned database. If selected studies are sufficiently homogeneous, we will perform a meta-analysis of reported results. In the event of a substantial heterogeneity, a qualitative systematic review will be performed. Discussion The results of this systematic review may help to better identify the patients affected by liver metastasis that could present low regeneration rates after neoadjuvant chemotherapy. These patients are at risk to develop liver failure after extended hepatectomies and therefore are not good candidates for such aggressive procedures. Systematic review registration PROSPERO registration number: CRD42020178481 (July 5, 2020).


2014 ◽  
Vol 22 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Sanjay Pandanaboyana ◽  
Alan White ◽  
Samir Pathak ◽  
Ernest L. Hidalgo ◽  
Giles Toogood ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document